Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
Yunwen XuThomas A BoyleBeini LyuShoshana H BallewElizabeth SelvinAlexander R ChangLesley A InkerMorgan E GramsJung-Im ShinPublished in: Journal of general internal medicine (2024)
In this real-word study, GLP-1RA was associated with a lower risk of AF compared with DPP4i, but no difference compared with SGLT2i, suggesting that cardiovascular benefits of GLP-1RA use may extend to prevention for AF in patients with diabetes. Our findings call for future randomized controlled trials to focus on the effects of GLP-1RA on AF prevention.
Keyphrases
- atrial fibrillation
- rheumatoid arthritis
- randomized controlled trial
- type diabetes
- heart failure
- cardiovascular disease
- disease activity
- systematic review
- ankylosing spondylitis
- left atrial appendage
- metabolic syndrome
- oral anticoagulants
- direct oral anticoagulants
- venous thromboembolism
- catheter ablation
- interstitial lung disease
- acute coronary syndrome
- left ventricular
- idiopathic pulmonary fibrosis